As part of agency initiatives to strengthen its oversight of human food and food products, FDA is revising inspection and compliance programs for all regulated products, at home and abroad. While an overriding aim is to improve FDA’s capability for monitoring and curbing contamination issues involving foods, the changes also involve revised oversight and inspection programs for medicines and other regulated products. Some of these actions arise from FDA’s greater reliance on remote oversight activities advanced during the global COVID pandemic, which encouraged more cooperation with foreign inspection programs. Others have been advanced by FDA for years, such as encouraging modern manufacturing processes and attention to quality issues to ensure reliable supplies to prevent drug shortages.
